dual gip/glp-1 receptor agonist Tirzepatide's Unique Mechanism of Action Frontiers | Clinical perspectives on
Description
at least 50% of patients receiving 10 or 15 mg of tirzepatide per week achieved a weight loss of 20% and more 6,59,60,61,62 .Tirzepatide was also superior to semaglutide at reducing levels of glycated hemoglobin 63
A 24-week phase 2 trial of tesofensine results in a mean weight loss of 4.5%, 9.2% and 10.6% at doses of 0.25 mg, 0.5 mg, and 1.0 mg, respectively, all compared to 2.0% for the placebo group (140)
as BMI increases above 25, average annual health care spending among Medicare beneficiaries increases
Cardia L, de Cleva R, Ferreira L, Gadducci AV, Estabile P, Santos Silva PR, et al
